Our current results clearly support a recent review of OSA heterogeneity regarding cardiovascular morbidities [1], suggesting that the response to CPAP treatment is modulated by genetic mechanisms, namely, in the current report, by TNF-α (-308G/A) gene polymorphism regarding the change in circulating levels of TNF-α from baseline. This evidence concerns the gene TNF and obstructive sleep apnea syndrome.